Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Biochemically Recurrent Prostate Cancer 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × darolutamide × Clear all
NCT05526248 2026-03-11

ARAMON

Bayer

Phase 2 Completed
28 enrolled 14 charts
Genitourinary

Biochemically Recurrent Prostate Cancer

NCT04157088 2023-08-04

DaroAcT

Bayer

Phase 2 Terminated
30 enrolled 25 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT01429064 2017-02-20

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Orion Corporation, Orion Pharma

Phase 2 Completed
76 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡